Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Metadata
Title
Recombinant von Willebrand factor: Potential Therapeutic Use
Author
Bernhard E. Fischer
Publication date
01-10-1999
Publisher
Kluwer Academic Publishers
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/1999
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1023/A:1008906103637

Other articles of this Issue 3/1999

Journal of Thrombosis and Thrombolysis 3/1999 Go to the issue

OriginalPaper

Randomized Clinical Trial of Urokinase versus Heparin in Unstable Angina

OriginalPaper

Pharmacokinetics and Hemostatic Effects of Saruplase in Patients with Acute Myocardial Infarction: Comparison of Infusion, Single-Bolus, and Split-Bolus Administration

OriginalPaper

Pathogenesis and Pathology of Coronary Heart Disease Syndromes

OriginalPaper

Antithrombin Agents as Adjuncts to Thrombolytic Therapy

OriginalPaper

Serum Homocysteine, MTHFR Gene Polymorphism, and Carotid Intimal-Medial Thickness in NIDDM Subjects

OriginalPaper

Coronary Artery Disease and Endothelial Nitric Oxide Synthase and Angiotensin-Converting Enzyme Gene Polymorphisms

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits